Intravenous self‐administration studies with l‐deprenyl (selegiline) in monkeys *

  title={Intravenous self‐administration studies with l‐deprenyl (selegiline) in monkeys *},
  author={Gail D. Winger and Sevil Yasar and S Stevens Negus and Steven R. Goldberg},
  journal={Clinical Pharmacology \& Therapeutics},
l‐Deprenyl and its stereoisomer d‐deprenyl did not maintain intravenous self‐administration behavior in rhesus monkeys. In contrast, l‐methamphetamine, the major metabolite of l‐deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self‐administration behavior. Treatment with l‐deprenyl doses up to 1.0 mg/kg before self‐administration sessions failed to alter self‐administration of either cocaine or l‐methamphetamine. Thus l‐deprenyl did not appear to have… 
Therapy with l‐deprenyl (selegiline) and relation to abuse liability *
The clinical aspects and rationale for therapy with l‐deprenyl for several neuropsychiatrie conditions, including major depression, Alzheimer's disease, and Parkinson's disease are reviewed, and evidence for efficacy is reviewed.
Effects of l-methamphetamine treatment on cocaine- and food-maintained behavior in rhesus monkeys
Results indicate that l-MA both shares discriminative stimulus effects with cocaine and reduces cocaine self-administration in a behaviorally selective manner.
Discriminative stimulus and reinforcing effects of p-fluoro-l-deprenyl in monkeys
p-Fluoro-l-deprenyl has methamphetamine-like discriminative-stimulus properties in squirrel monkeys that appear at higher doses than for its parent compound, l- Deprenyl.
Reinforcing and Stimulant-Like Effects of Methamphetamine Isomers in Rhesus Macaques
L-MA demonstrated lower abuse liability compared to commonly abused stimulants and produced few untoward effects, which support l-MA's potential as a pharmacotherapy for stimulant addiction.
Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.
There is evidence that l-amphetamine and l-methamphetamine have some qualitatively different actions than their d-isomer counterparts on EEG and cognitive functioning which might result in beneficial clinical effects and complement beneficial clinical actions of l-deprenyl itself.
A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline), and d-deprenyl under a second-order schedule in squirrel monkeys
Under conditions where drug-seeking and drug-taking behaviors are actively maintained by d-amphetamine, l-deprenyl, at doses that specifically inhibit type B monoamine oxidase, may not be effective as a treatment.
Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats
High-dose selegiline can attenuate extinction responding and morphine-reinforced behavior, and these effects may be mediated by psychostimulant metabolites.


Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential
Evaluation of l-deprenyl for cocaine-like abuse liability is a relevant topic of research because the reinforcing effects of cocaine may be mediated by inhibition of dopamine reuptake, and l-Deprenyl, in addition to its MAO-B actions, also inhibits dopamine reptake.
Self-administration of optical isomers of amphetamine and methylamphetamine by rats.
  • R. Yokel, R. Pickens
  • Psychology, Biology
    The Journal of pharmacology and experimental therapeutics
  • 1973
Qualitative effects were similar with both isomers of each drug: alternating periods of responding and no responding, weight loss, body irritation and typically death within two weeks with onset of self-administration.
Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.
L-Deprenyl produced clear generalization to the d-amphetamine stimulus only at very high doses of 17.0 to 30.0 mg/kg, doses about 10-fold higher than those that have a selective action on MAO-B vs.MAO-A and which start to have marked rate decreasing actions on food-reinforced responding.
Characteristics of β-phenethylamine self-administration by dog
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
The data suggest that the stimulatory effect on locomotor activity and dopamine synthesis is not related to a monoamine oxidase-B blocking action of the drug or to a putative effect on DA reuptake, but rather to effects of metabolites of thedrug (e.g., l-methamphetamine).
The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
The treatment for two or four weeks with 0.25 mg/kg sc (-)deprenyl, a specific MAO B inhibitor, enhanced the turnover rate of dopamine and the fractional rate constant of dopamine efflux, reflecting an increased utilization rate of this amine in the striatum.
Self-administration of the endogenous trace amines beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs.
Data indicate that the endogenous trace amines beta-phenylethylamine, phenylethanolamine and the N-methyl homolog of beta-PNL can function as reinforcers and are compatible with hypotheses that they may play a physiological role in the reinforcement process or in neuropsychiatric disorders.